Status
Conditions
About
5 and 10 years follow-up of the oxyop study.
Full description
Oxyop (NCT02652520 PHRC) was a safety study evaluating the use of an oxygen carrier HEMO2life® as an additive in organ preservation solution in 60 transplanted kidneys. This was a national multicenter (6 centers) open-labeled safety study on HEMO2life® that included 58 recipients. The first patient was included on March 24th, 2016 and the study was completed on February 23th, 2018 (1 year of recruitment and 1 year of follow-up). Some efficacy secondary end points using a paired analysis was also analyzed (local kidney receiving HEMO2life® versus contralateral kidney transplanted elsewhere in France). Oxyop 5 and 10 years aims to analyse 5 and 10 years results.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
116 participants in 2 patient groups
Loading...
Central trial contact
Christelle RATAJCZAK; Yannick Le Meur, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal